Eyenovia, Inc. Overview
Pro stress-test →Eyenovia is a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-doses (6-8 µL) of active pharmaceutical ingredients. The company is a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia. The Optejet device represents a transformative platform for topical eye drug delivery across multiple therapeutic areas.
Strategic Profile
Pro stress-test →The micro-dosing technology has the potential to replace traditional macro-dosing applications (e.g. conventional eye droppers that deliver 30-50 µL) and achieve similar pharmacologic effects while reducing adverse effects. The company is developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications.
Competitive Landscape
Pro stress-test →Eyenovia develops micro-formulations of common eye therapies using its proprietary micro-dosing technology. Key competitors include traditional ophthalmic drug makers (Bausch + Lomb, Alcon) and other innovative delivery platforms. The company's primary competitive advantage is the Optejet platform's ability to enable lower dosing, reduced side effects, and improved patient compliance compared to conventional eye drops.
Industry Context
Eyenovia, Inc. operates in Ophthalmic drug delivery devices and pharmaceutical products.
Key facts
Founded: N/A · Headquarters: New York, US · Employees: N/A · Revenue: N/A · Market cap: N/A